Vicarious Surgical Inc. (NYSE:RBOT) Reports Narrower Q2 2025 Loss Amid Cost Optimization Efforts

Vicarious Surgical Inc. (NYSE:RBOT) reported its second-quarter 2025 financial results, revealing a net loss per share of $2.23, which was narrower than the analyst consensus estimate of a $2.55 loss. The company reported no revenue for the quarter, in line with expectations, as it continues to focus on developing its surgical robotics platform.

Key Financial Highlights

• Operating Expenses: Declined 24% year-over-year to $13.5 million, reflecting cost optimization efforts.
• R&D Expenses: Decreased to $9.1 million from $10.9 million in Q2 2024, as the company progresses toward commercialization.
• Cash Position: Ended the quarter with $24 million in cash and investments, with a quarterly cash burn of $13.4 million. Full-year cash burn is projected at approximately $50 million.
• Net Loss: GAAP net loss improved to $13.2 million ($2.23 per share) from $15.2 million ($2.59 per share) in the prior-year period.

Market Reaction

Following the earnings release, Vicarious Surgical's stock saw modest after-hours movement, with a slight uptick of ~0.29%. Over the past month, shares have gained 6.5%, suggesting cautious optimism among investors as the company advances its robotic surgery system.

Leadership Transition & Strategic Focus

The earnings report coincided with a leadership change, with Stephen From assuming the CEO role while co-founder Adam Sachs transitions to President. From emphasized the company’s potential to "reshape the standard of care" with its single-port surgical robot, the Vicarious Surgical System.

Looking Ahead

Analysts currently expect no revenue for fiscal 2025, with a projected full-year EPS loss of $9.63. For Q3 2025, estimates point to a loss of $2.45 per share. The company did not provide specific financial guidance beyond its cash burn outlook.

For more detailed earnings estimates and historical performance, view the full earnings and estimates breakdown.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.